

10/ 808,496

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS INTER	General Internet Information		
NEWS LOGIN	Welcome Banner and News Items		
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN		
NEWS WWW	CAS World Wide Web Site (general information)		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:48:16 ON 22 APR 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10/ 808,496

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:48:25 ON 22 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7
DICTIONARY FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10808496.str



chain nodes :

17

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

1-10 13-17

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15

10/ 808,496

exact/norm bonds :
1-10 2-7 3-9 7-8 8-9 13-17
exact bonds :
10-11 10-15 11-12 12-13 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 10 :


G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom
Generic attributes :
17:
Number of Carbon Atoms : 7 or more
Number of Hetero Atoms : 2 or more
Type of Ring System : Polycyclic

Element Count :
Node 17: Limited
C,C8
N,N2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample
SAMPLE SEARCH INITIATED 13:48:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 215 TO ITERATE

10/ 808,496

100.0% PROCESSED 215 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3421 TO 5179
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 13:49:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3950 TO ITERATE

100.0% PROCESSED 3950 ITERATIONS
SEARCH TIME: 00.00.01

10 ANSWERS

L3 10 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 13:49:17 ON 22 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Apr 2005 VOL 142 ISS 18
FILE LAST UPDATED: 21 Apr 2005 (20050421/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 2 L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171900 CAPLUS

DOCUMENT NUMBER: 136:216764



TITLE: Process for the preparation of 3-(6-piperidinylpurin-9-yl)propionates as vitronectin receptor antagonists

INVENTOR(S): Peyman, Anuschirwan; Schubert, Gerrit

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany


SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018384	A1	20020307	WO 2001-EP9985	20010829
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, GR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10042655	A1	20020314	DE 2000-10042655	20000831
AU 2001093791	A5	20020313	AU 2001-93791	20010829
EP 1315728	A1	20030604	EP 2001-974220	20010829
EP 1315728	B1	20041027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507544	T2	20040311	JP 2002-523899	20010829
AT 280769	E	20041115	AT 2001-974220	20010829
US 2004248907	A1	20041209	US 2003-363450	20030401
PRIORITY APPLN. INFO.:			DE 2000-10042655	A 20000831
			WO 2001-EP9985	W 20010829
OTHER SOURCE(S):			CASREACT 136:216764; MARPAT 136:216764	
GI				



- AB The present invention relates to a process for the preparation of vitronectin receptor antagonists I [wherein R = G1 or G2; R1, R2, R3, and R4 = independently H, F, Cl, CN, (un)substituted alkyl, cycloalkyl(alkyl), or aryl(alkyl), or R6OR7, R6R6'NR7, R6COR7, R6SO2N(R9)R7, R6CON(R9)R7, R6CON(R5)R7, R6N(R9)CON(R9)R7, R6N(R9)SO2N(R9)R7, R6SO2R7, R6SCON(R9)R7, R6N(R9)COR7, R6N(R9)SO2R7, R6N(R9)R7, or heterocyclyl; R5 = OH, (aryl)alkoxy, alkylcarbonyloxyalkoxy, or cyclo(alkyl)alkoxy; R6 and R6' = independently (un)substituted alkyl, cycloalkyl(alkyl), aryl(alkyl), or heterocyclyl; R7 = independently alkanediyl or a direct bond; R9 = H or alkyl; and stereoisomers and salts thereof] by coupling a 9-chloropurine I [R = Cl] to a 4-substituted piperidine and comprises an efficient method for the preparation of I [R = Cl]. In contrast to prior art, the process according to the invention gives good yields in a lower number of steps and can be used advantageously for the syntheses on a relatively large scale. For example, Et (2S)-2-(naphthalene-1-sulfonylamino)-3-aminopropionate was aminated with 4,6-dichloro-5-nitropyrimidine in THF in the presence of TEA and then reduced to the amine using SnCl₂ in EtOH. Cyclocondensation with tri-Et orthoformate in N-methylpyrrolidone in the presence of EtSO₃H gave the 6-chloropurine. Reaction with 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-[1,8]naphthyridine in DMF and diisopropylethylamine at 70°C for 3 h afforded the piperidinylpurinylpropionate II.
- IT **402501-87-5P**, Ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-[6-[4-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)piperidin-1-yl]purin-9-yl]propionate
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (target compound; process for preparation purinylpropionate vitronectin receptor antagonists starting from nitropyrimidines and aminopropionates)
- RN 402501-87-5 CAPLUS
- CN 9H-Purine-9-propanoic acid, α -[(1-naphthalenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, ethyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:10662 CAPLUS

DOCUMENT NUMBER: 134:71600

TITLE: Naphthyridine derivatives, processes for their preparation, their use as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compositions comprising them

INVENTOR(S): Peyman, Anuschirwan; Scheunemann, Karl-Heinz; Gourvest, Jean-Francois; Ruxer, Jean-Marie; Gadek, Thomas R.

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Genentech, Inc.

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065207	A1	20010103	EP 1999-112636	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2376668	AA	20010111	CA 2000-2376668	20000626
WO 2001002398	A1	20010111	WO 2000-EP5920	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ,				

EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000012129	A	20020507	BR 2000-12129	20000626
EP 1210348	A1	20020605	EP 2000-945825	20000626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200103856	T2	20020621	TR 2001-200103856	20000626
JP 2003503496	T2	20030128	JP 2001-507835	20000626
NZ 516058	A	20030131	NZ 2000-516058	20000626
EE 200100711	A	20030415	EE 2001-711	20000626
AU 775386	B2	20040729	AU 2000-59787	20000626
TW 593319	B	20040621	TW 2000-89117925	20000901
BG 106257	A	20021031	BG 2001-106257	20011220
HR 2001000946	A1	20030228	HR 2001-946	20011221
NO 2001006404	A	20020301	NO 2001-6404	20011228
ZA 2002000016	A	20030102	ZA 2002-16	20020102
US 6743800	B1	20040601	US 2002-30301	20020320
US 2004198718	A1	20041007	US 2004-808496	20040324
PRIORITY APPLN. INFO.:			EP 1999-112636	A 19990702
			WO 2000-EP5920	W 20000626
			US 2002-30301	A3 20020320

OTHER SOURCE(S): MARPAT 134:71600
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to compds. I. G is $-(CR1R2)_n-A-(CR1R2)_m-(CR1R3)_i-(CR1R2)_q-R4$. A is a direct bond, $-C(O)NR5-$, $-NR5C(O)-$, $-C(O)-$, $-NR5-$, $-O-$, $-S-$, $-S(O)-$, $-S(O)2-$, $(C2-C4)alkynediyl$, $(C2-C4)alkenediyl$, $(C5-C14)arylene$ where in the arylene residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or a divalent residue of a 3-7-membered saturated or unsatd. ring which can contain 1-2 ring heteroatoms N, S and O and which can be monosubstituted or disubstituted by residues :O, :S and R3. B is $(C1-C18)alkyl$, $(C3-C14)cycloalkyl$, $(C3-C14)cycloalkyl(C1-C8)alkyl$, $(C5-C14)aryl$, $(C5-C14)aryl(C1-C8)alkyl$, $(C5-C14)heteroaryl$, $(C5-C14)heteroaryl(C1-C8)alkyl$, F, Cl, Br, OH, CN, CF₃, NO₂, CO₂H, $(C1-C6)alkoxy$, $(C1-C6)alkoxy(C1-C6)alkyl$, $(C1-C6)alkoxycarbonyl$, $(C1-C6)alkylcarbonyl$, $(C5-C14)arylcarbonyl$, $(C1-C6)alkylaminocarbonyl$, $(C1-C6)alkoxy(C1-C6)alkoxy$, $(C5-C14)aryl(C1-C8)alkylcarbonyl$, $(C1-C6)alkanoylamino$, $(C1-C6)alkylsulfonylamino$, $(C5-C14)arylsulfonylamino$, $(C1-C6)alkylamino$, $di((C1-C6)alkyl)amino$, $(C1-C6)alkylsulfonyl$, $aminosulfonyl$, $(C5-C14)arylsulfonyl$, $(C5-C14)aryl(C1-C8)alkylsulfonyl$, $(C5-C14)aryl$ or $(C5-C14)heteroaryl$, where all residues B are independent of one another and can be identical or different. X is H, NR₆R₆', F, Cl, Br, OR₆, SR₆, $hydroxy(C1-C6)alkyl-NH-$, $(hydroxy(C1-C6)alkyl)2N-$, $amino(C1-C6)alkyl-NH-$, $(amino(C1-C6)alkyl)2N-$, $hydroxy(C1-C6)alkyl-O-$, $hydroxy(C1-C6)alkyl-S-$ or $-NH-C(O)-R6$. Y is R₅, F, Cl, Br, CN, NR₆R₆', OR₆, SR₆ or $hydroxy(C1-C6)alkyl-NH-$. Z is N or CH. R₁ and R₂ are H, F, Cl, CN, NO₂, $(C1-C10)alkyl$, $(C3-C14)cycloalkyl$, $(C3-C14)cycloalkyl(C1-C8)alkyl$, $(C5-C14)aryl$, $(C5-C14)aryl(C1-C8)alkyl$, $(C5-C14)heteroaryl$, $(C5-C14)heteroaryl(C1-C8)alkyl$, R₆-O-R₇, R₆-S(O)p-R₇, R₆S(O)2NHR₇, R₆O(C)NHR₇ or R₆R₆'N-R₇, where all residues R₁ and R₂ are independent of one another and can be identical or different. R₃ is H, F, Cl, CN, NO₂,

(C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6R6'N-R7, R6C(O)-O-R7, R6C(O)R7, R6OC(O)R7, R6N(R6')C(O)OR7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, R6C(O)N(R5)R7, R6N(R6')C(O)N(R5)R7, R6N(R6')S(O)pN(R5)R7, R6S(O)pR7, R6SC(O)N(R5)R7, R6N(R6')C(O)R7 or R6N(R6')S(O)pR7, where alkyl can be monounsaturated or polyunsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by R6, F, Cl, Br, CN, CF₃, R6R6'NR7, NO₂, R6OC(O)R7, R6C(O)R7, R6N(R6')C(O)R7, R6N(R6')S(O)pR7 or R6-O-R7, and where all residues R3 are independent of one another and can be identical or different. R4 is -C(O)R8, -C(S)R8, -S(O)pR8, -P(O)R8R8' or a residue of a 4-8-membered saturated or unsaturated heterocycle which contains 1-4 heteroatoms N, O and S. R5 is H, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl or (C5-C14)aryl(C1-C8)alkyl, where all residues R5 are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl(C1-C8)alkyl where aryl, heteroaryl, cycloalkyl and alkyl can be substituted 1-3 times by identical or different substituents F, Cl, Br, CN, CF₃, NO₂, CO₂H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)arylcabonyl, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, (C1-C6)alkylaminosulfonyl, (C5-C14)arylaminosulfonyl, (C5-C14)aryl(C1-C8)alkylaminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl(C1-C8)alkylsulfonyl, (C5-C14)aryl and (C5-C14)heteroaryl, and where all residues R6 and R6' are independent of one another and can be identical or different. R7 is (C1-C4)alkanediyl or a direct bond, where all residues R7 are independent of one another and can be identical or different. R8 and R8' are OH, (C1-C8)alkoxy, (C5-C14)aryl(C1-C8)alkoxy, (C5-C14)aryloxy, (C1-C8)alkylcarbonyloxy(C1-C4)alkoxy, (C5-C14)aryl(C1-C8)alkylcarbonyloxy(C1-C8)alkoxy, NR6R6', di((C1-C8)alkyl)amino)carbonylmethyloxy, di((C5-C14)aryl(C1-C8)alkyl)amino)carbonylmethyloxy, (C5-C14)arylmino, the residue of an amino acid, N-((C1-C4)alkyl)piperidin-4-yloxy, 2-methylsulfonylethoxy, 1,3-thiazol-2-ylmethyloxy, 3-pyridylmethyloxy, 2-(di((C1-C4)alkyl)amino)ethoxy or the residue Q-(CH₃)₃N⁺-CH₂-CH₂-O- in which Q- is a physiol. tolerable anion, where all residues R8 and R8' are independent of one another and can be identical or different. N is 0-5; m is 0-5; i is 0-1; q is 0-2; r is 0-2; s is 0-3; t is 0-8; p is 0-2, where all nos. p are independent of one another and can be identical or different. The claimed compds. also include stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure shown I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compns. comprising them. The process of preparation comprises reacting II (L1 = leaving group) with III or IV; B, G, X, Y, r, s and t are defined as above but wherein functional groups can also be present in the form of

precursor groups or in protected form. For example, (2S)-2-benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester could be made from 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-1,8-naphthyridine and (S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester in DMF in the presence of NETiPr₂; the ester was then hydrolyzed by CF₃CO₂H to give the desired compound

IT **315240-30-3P**, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester **315240-32-5P**, (2S)-2-Amino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester **315240-34-7P**, (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; naphthyridine derivs., processes for preparation, uses as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compns. comprising them)

RN 315240-30-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[(phenylmethoxy) carbonyl] amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-32-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α -amino-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-34-7 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[(phenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **315240-14-3P**, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
315240-16-5P, (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
315240-18-7P, (2S)-2-(4-Chlorobenzenesulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
315240-20-1P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
315240-22-3P, (2S)-3-(6-(4-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid
315240-24-5P, (2S)-2-(Butane-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (naphthyridine derivs., processes for preparation, uses as vitronectin
 receptor antagonists and inhibitors of cell adhesion, and
 pharmaceutical compns. comprising them)

RN 315240-14-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[(phenylmethoxy)carbonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (α S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-16-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[(phenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-18-7 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[(4-chlorophenyl)sulfonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (α S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-20-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[(1-naphthalenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-22-3 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]- α -[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-24-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[(butylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:48:16 ON 22 APR 2005)

FILE 'REGISTRY' ENTERED AT 13:48:25 ON 22 APR 2005

L1 STRUCTURE UPLOADED

L2 0 S L1 SAMPLE

L3 10 S L1 FUL

FILE 'CAPLUS' ENTERED AT 13:49:17 ON 22 APR 2005

10/ 808,496

L4 2 S L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.33

171.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.46

-1.46

STN INTERNATIONAL LOGOFF AT 13:49:48 ON 22 APR 2005